{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T15:06:09Z","timestamp":1791644769323,"version":"4.3.4"},"reference-count":27,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1016\/j.ophtha.2013.09.015","type":"journal-article","created":{"date-parts":[[2013,11,27]],"date-time":"2013-11-27T02:15:42Z","timestamp":1385518542000},"page":"475-483","source":"Crossref","is-referenced-by-count":196,"title":["Lifitegrast Ophthalmic Solution 5.0% for Treatment of Dry Eye Disease"],"prefix":"10.1016","volume":"121","clinical-trial-number":[{"clinical-trial-number":"nct01421498","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01636206","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"John D.","family":"Sheppard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gail L.","family":"Torkildsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Lonsdale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Francis A.","family":"D'Ambrosio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene B.","family":"McLaurin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Eiferman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn S.","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles P.","family":"Semba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ophtha.2013.09.015_bib1","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1542-0124(12)70081-2","article-title":"The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye Workshop (2007)","volume":"5","year":"2007","journal-title":"Ocul Surf"},{"key":"10.1016\/j.ophtha.2013.09.015_bib2","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1001\/archopht.118.9.1264","article-title":"Prevalence of and risk factors for dry eye syndrome","volume":"118","author":"Moss","year":"2000","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2013.09.015_bib3","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1167\/iovs.04-1326","article-title":"The controlled-environment chamber: a new mouse model of dry eye","volume":"46","author":"Barabino","year":"2005","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2013.09.015_bib4","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1097\/ICO.0b013e3181a16578","article-title":"Analysis of inflammatory cytokines in the tears of dry eye patients","volume":"28","author":"Massingale","year":"2009","journal-title":"Cornea"},{"key":"10.1016\/j.ophtha.2013.09.015_bib5","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1001\/archophthalmol.2011.364","article-title":"Dry eye disease: an immune-mediated ocular surface disorder","volume":"130","author":"Stevenson","year":"2012","journal-title":"Arch Ophthalmol"},{"issue":"Suppl","key":"10.1016\/j.ophtha.2013.09.015_bib6","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1097\/ICO.0b013e31817f4075","article-title":"Epithelial-immune cell interaction in dry eye","volume":"27","author":"Pflugfelder","year":"2008","journal-title":"Cornea"},{"key":"10.1016\/j.ophtha.2013.09.015_bib7","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/j.1600-065X.2007.00537.x","article-title":"The role of the integrin LFA-1 in T-lymphocyte migration","volume":"218","author":"Smith","year":"2007","journal-title":"Immunol Rev"},{"key":"10.1016\/j.ophtha.2013.09.015_bib8","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1038\/ni1103-1052","article-title":"LFA-1: more than just T cell Velcro","volume":"4","author":"Shimizu","year":"2003","journal-title":"Nature Immunol"},{"key":"10.1016\/j.ophtha.2013.09.015_bib9","first-page":"2609","article-title":"Conjunctival T-cell populations in Sj\u00f6gren's and non-Sj\u00f6gren's patients with dry eye","volume":"43","author":"Stern","year":"2002","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2013.09.015_bib10","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.exer.2003.10.024","article-title":"ICAM-1 expression predisposes ocular tissues to immune-based inflammation in dry eye patients and Sj\u00f6gren's syndrome-like MRL\/lpr mice","volume":"78","author":"Gao","year":"2004","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.ophtha.2013.09.015_bib11","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ajo.2008.08.032","article-title":"Tear cytokine profiles in dysfunctional tear syndrome","volume":"147","author":"Lam","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2013.09.015_bib12","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1021\/ml2002482","article-title":"Discovery and development of potent LFA-1\/ICAM-1 antagonist SAR 1118 as an ophthalmic solution for treating dry eye","volume":"3","author":"Zhong","year":"2012","journal-title":"ACS Med Chem Lett [serial online]"},{"key":"10.1016\/j.ophtha.2013.09.015_bib13","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1126\/science.295.5557.1086","article-title":"Generation of an LFA-1 antagonist by the transfer of the ICAM-1 immunoregulatory epitope to a small molecule","volume":"295","author":"Gadek","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.ophtha.2013.09.015_bib14","doi-asserted-by":"crossref","first-page":"10836","DOI":"10.1073\/pnas.96.19.10836","article-title":"Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition","volume":"96","author":"Miyamoto","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ophtha.2013.09.015_bib15","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S0014-4835(05)80001-6","article-title":"Monoclonal antibodies against CD54 (ICAM-1) and CD11a (LFA-1) prevent and inhibit endotoxin-induced uveitis","volume":"60","author":"Whitcup","year":"1995","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.ophtha.2013.09.015_bib16","doi-asserted-by":"crossref","first-page":"3174","DOI":"10.1167\/iovs.09-5078","article-title":"The pharmacologic assessment of a novel lymphocyte function-associated antigen-1 antagonist (SAR 1118) for the treatment of keratoconjunctivitis sicca in dogs","volume":"52","author":"Murphy","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2013.09.015_bib17","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.ajo.2011.11.003","article-title":"A\u00a0phase 2 randomized, double-masked, placebo-controlled study of a novel integrin antagonist (SAR 1118) for the treatment of dry eye","volume":"153","author":"Semba","year":"2012","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2013.09.015_bib18","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S1542-0124(12)70196-9","article-title":"Methodologies for the study of ocular surface disease","volume":"3","author":"Ousler","year":"2005","journal-title":"Ocul Surf"},{"key":"10.1016\/j.ophtha.2013.09.015_bib19","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1001\/archopht.118.5.615","article-title":"Reliability and validity of the Ocular Surface Disease Index","volume":"118","author":"Schiffman","year":"2000","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2013.09.015_bib20","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S0161-6420(99)00176-1","article-title":"CsA Phase 3 Study Group. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease","volume":"107","author":"Sall","year":"2000","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2013.09.015_bib21","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1097\/01.ico.0000133993.14768.a9","article-title":"Double-masked, placebo-controlled safety and efficacy trial of diquafosol tetrasodium (INS365) ophthalmic solution for treatment of dry eye","volume":"23","author":"Tauber","year":"2004","journal-title":"Cornea"},{"key":"10.1016\/j.ophtha.2013.09.015_bib22","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.ajo.2009.09.023","article-title":"Demonstration of efficacy in the treatment of dry eye disease with 0.18% sodium hyaluronate ophthalmic solution (Vismed, Rejena)","volume":"149","author":"Vogel","year":"2010","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2013.09.015_bib23","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1097\/01.ico.0000133997.07144.9e","article-title":"The lack of association between signs and symptoms in patients with dry eye disease","volume":"23","author":"Nichols","year":"2004","journal-title":"Cornea"},{"key":"10.1016\/j.ophtha.2013.09.015_bib24","series-title":"Principles and Practice of Clinical Trial Medicine","first-page":"169","article-title":"Patient selection and sampling","author":"Chin","year":"2008"},{"key":"10.1016\/j.ophtha.2013.09.015_bib25","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1097\/00003226-200210000-00007","article-title":"Dry Eye Investigation (DREI) Study Group. Use of the Dry Eye Questionnaire to measure symptoms of ocular irritation in patients with aqueous tear deficient dry eye","volume":"21","author":"Begley","year":"2002","journal-title":"Cornea"},{"key":"10.1016\/j.ophtha.2013.09.015_bib26","doi-asserted-by":"crossref","first-page":"4753","DOI":"10.1167\/iovs.03-0270","article-title":"The relationship between habitual patient-reported symptoms and clinical signs among patients with dry eye of varying severity","volume":"44","author":"Begley","year":"2003","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2013.09.015_bib27","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1089\/jop.2009.0105","article-title":"Safety and pharmacokinetics of a novel lymphocyte function-associated antigen-1 antagonist ophthalmic solution (SAR 1118) in healthy adults","volume":"27","author":"Semba","year":"2011","journal-title":"J\u00a0Ocul Pharmacol Ther"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016164201300835X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016164201300835X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,8]],"date-time":"2018-10-08T18:21:13Z","timestamp":1539022873000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016164201300835X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["S016164201300835X"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2013.09.015","relation":{},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2014,2]]}}}